Truist maintains Buy on Globus Medical, cuts target to $100
Truist Securities analyst Richard Newitter maintained a Buy rating on Globus Medical but lowered the price target to $100 from $115. The adjustment reflects a revised valuation benchmark for the NYSE-listed stock.
*this image is generated using AI for illustrative purposes only.
Truist Securities analyst Richard Newitter has maintained a Buy rating for Globus Medical while lowering the price target to $100 from $115. The adjustment reflects a revised valuation benchmark for the stock, which trades on the NYSE under the ticker GMED. This follows a previous rating action by RBC Capital, which had also adjusted its target to $115 while maintaining an Outperform rating.
Rating and Valuation
The Buy rating indicates that the firm expects the stock to perform better than the market average. The reduction in the price target suggests a recalibration of the company's near-term valuation prospects.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $115 |
| New Price Target | $100 |
What factors could drive Globus Medical's stock to rebound to the previous $115 price target?
How might the revised valuation benchmark impact investor sentiment toward GMED in the short term?
What competitive or market trends could influence Globus Medical's future performance?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
